Lineage Cell Therapeutics Book Value Per Share Growth & History (LCTX)
Lineage Cell Therapeutics's book value per share was $0.18 for fiscal 2025.
View full Lineage Cell Therapeutics company overviewLineage Cell Therapeutics annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $0.18 | -$0.17 | −48.47% |
| 2024 | 2024-12-31 | $0.36 | -$0.01 | −1.88% |
| 2023 | 2023-12-31 | $0.36 | -$0.07 | −15.94% |
| 2022 | 2022-12-31 | $0.43 | -$0.11 | −20.76% |
| 2021 | 2021-12-31 | $0.54 | -$0.08 | −13.40% |
| 2020 | 2020-12-31 | $0.63 | -$0.13 | −16.67% |
| 2019 | 2019-12-31 | $0.75 | $0.03 | +3.92% |
| 2018 | 2018-12-31 | $0.73 | -$0.56 | −43.40% |
| 2017 | 2017-12-31 | $1.28 | $0.13 | +11.73% |
| 2016 | 2016-12-31 | $1.15 | $0.86 | +301.89% |
| 2015 | 2015-12-31 | $0.29 | -$0.14 | −32.23% |
| 2014 | 2014-12-31 | $0.42 | $0.16 | +61.43% |
| 2013 | 2013-12-31 | $0.26 | $0.07 | +34.46% |
| 2012 | 2012-12-31 | $0.19 | -$0.39 | −66.78% |
| 2011 | 2011-12-31 | $0.58 | -$0.21 | −26.88% |
| 2010 | 2010-12-31 | $0.80 | — | — |
Lineage Cell Therapeutics quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0.24 | $0.03 | +13.68% |
| Q1 2026 | 2026-03-31 | $0.22 | -$0.13 | −37.55% |
| Q4 2025 | 2025-12-31 | $0.18 | -$0.17 | −48.47% |
| Q3 2025 | 2025-09-30 | $0.10 | -$0.25 | −72.70% |
| Q2 2025 | 2025-06-30 | $0.21 | -$0.15 | −41.42% |
| Q1 2025 | 2025-03-31 | $0.35 | -$0.04 | −9.78% |
| Q4 2024 | 2024-12-31 | $0.36 | -$0.01 | −1.88% |
| Q3 2024 | 2024-09-30 | $0.35 | -$0.04 | −9.96% |
| Q2 2024 | 2024-06-30 | $0.36 | -$0.05 | −13.17% |
| Q1 2024 | 2024-03-31 | $0.38 | -$0.03 | −7.35% |
| Q4 2023 | 2023-12-31 | $0.36 | -$0.07 | −15.94% |
| Q3 2023 | 2023-09-30 | $0.39 | -$0.08 | −16.23% |
| Q2 2023 | 2023-06-30 | $0.42 | -$0.07 | −14.65% |
| Q1 2023 | 2023-03-31 | $0.41 | -$0.10 | −18.81% |
| Q4 2022 | 2022-12-31 | $0.43 | -$0.11 | −20.76% |
| Q3 2022 | 2022-09-30 | $0.46 | -$0.25 | −35.15% |
| Q2 2022 | 2022-06-30 | $0.49 | -$0.26 | −34.63% |
| Q1 2022 | 2022-03-31 | $0.51 | -$0.22 | −29.77% |
| Q4 2021 | 2021-12-31 | $0.54 | -$0.08 | −13.40% |
| Q3 2021 | 2021-09-30 | $0.72 | $0.11 | +17.76% |
| Q2 2021 | 2021-06-30 | $0.75 | $0.08 | +12.49% |
| Q1 2021 | 2021-03-31 | $0.73 | $0.02 | +2.14% |
| Q4 2020 | 2020-12-31 | $0.63 | -$0.13 | −16.67% |
| Q3 2020 | 2020-09-30 | $0.61 | -$0.17 | −22.20% |
| Q2 2020 | 2020-06-30 | $0.66 | -$0.23 | −25.54% |
| Q1 2020 | 2020-03-31 | $0.71 | -$0.37 | −34.14% |
| Q4 2019 | 2019-12-31 | $0.75 | $0.03 | +3.92% |
| Q3 2019 | 2019-09-30 | $0.78 | -$0.57 | −42.01% |
| Q2 2019 | 2019-06-30 | $0.89 | $0.10 | +11.99% |
| Q1 2019 | 2019-03-31 | $1.08 | $0.29 | +36.97% |
| Q4 2018 | 2018-12-31 | $0.73 | -$0.56 | −43.40% |
| Q3 2018 | 2018-09-30 | $1.35 | -$0.36 | −21.23% |
| Q2 2018 | 2018-06-30 | $0.80 | -$0.79 | −49.89% |
| Q1 2018 | 2018-03-31 | $0.79 | -$0.90 | −53.38% |
| Q4 2017 | 2017-12-31 | $1.28 | $0.13 | +11.73% |
| Q3 2017 | 2017-09-30 | $1.71 | $0.55 | +47.39% |
| Q2 2017 | 2017-06-30 | $1.59 | $0.75 | +88.35% |
| Q1 2017 | 2017-03-31 | $1.69 | $1.57 | +1308.28% |
| Q4 2016 | 2016-12-31 | $1.15 | $0.86 | +301.89% |
| Q3 2016 | 2016-09-30 | $1.16 | $1.00 | +630.75% |
| Q2 2016 | 2016-06-30 | $0.84 | $0.67 | +390.46% |
| Q1 2016 | 2016-03-31 | $0.12 | -$0.17 | −58.69% |
| Q4 2015 | 2015-12-31 | $0.29 | -$0.14 | −32.23% |
| Q3 2015 | 2015-09-30 | $0.16 | $0.05 | +45.12% |
| Q2 2015 | 2015-06-30 | $0.17 | -$0.04 | −20.22% |
| Q1 2015 | 2015-03-31 | $0.29 | $0.02 | +9.00% |
| Q4 2014 | 2014-12-31 | $0.42 | $0.16 | +61.43% |
| Q3 2014 | 2014-09-30 | $0.11 | -$0.12 | −52.91% |
| Q2 2014 | 2014-06-30 | $0.22 | -$0.16 | −42.69% |
| Q1 2014 | 2014-03-31 | $0.27 | -$0.04 | −11.61% |
| Q4 2013 | 2013-12-31 | $0.26 | $0.07 | +34.46% |
| Q3 2013 | 2013-09-30 | $0.23 | -$0.11 | −32.48% |
| Q2 2013 | 2013-06-30 | $0.38 | -$0.09 | −19.67% |
| Q1 2013 | 2013-03-31 | $0.30 | -$0.19 | −38.90% |
| Q4 2012 | 2012-12-31 | $0.19 | -$0.39 | −66.78% |
| Q3 2012 | 2012-09-30 | $0.34 | -$0.34 | −49.84% |
| Q2 2012 | 2012-06-30 | $0.47 | -$0.27 | −36.70% |
| Q1 2012 | 2012-03-31 | $0.49 | — | — |
| Q4 2011 | 2011-12-31 | $0.58 | -$0.21 | −26.88% |
| Q3 2011 | 2011-09-30 | $0.69 | — | — |
| Q2 2011 | 2011-06-30 | $0.74 | — | — |
| Q4 2010 | 2010-12-31 | $0.80 | — | — |
Lineage Cell Therapeutics book value per share trends
Over the last five fiscal years, Lineage Cell Therapeutics's book value per share decreased from $0.63 to $0.18, a change of -$0.45. The latest reported quarter, Q2 2026, shows $0.24.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lineage Cell Therapeutics source filings ↗